Form 4: Enliven Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Helen Louise Collins, CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc., sold 5,000 shares of common stock on July 17, 2026.
Summary
- Option exercise/conversion: acquired 5,000 Common Stock at $2.48 ($12,400) on July 17, 2026; holds 30,000 after (Direct).
- Open-market sale: disposed of 231 Common Stock at $50.05 ($11,563) on July 17, 2026; holds 29,769 after (Direct).
- Open-market sale: disposed of 459 Common Stock at $51.55 ($23,660) on July 17, 2026; holds 29,310 after (Direct).
- Open-market sale: disposed of 2,063 Common Stock at $52.39 ($108,085) on July 17, 2026; holds 27,247 after (Direct).
- Open-market sale: disposed of 2,184 Common Stock at $53.42 ($116,669) on July 17, 2026; holds 25,063 after (Direct).
- Open-market sale: disposed of 63 Common Stock at $53.92 ($3,397) on July 17, 2026; holds 25,000 after (Direct).
- Option exercise/conversion: disposed of 5,000 Stock Option (right to buy) on July 17, 2026; holds 116,268 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $263,373 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Helen Louise Collins — Officer (CHIEF MEDICAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Option exercise/conversion | Common Stock | 5,000 | $2 | $12.4K | 30,000 |
| 2026-07-17 | Open-market sale | Common Stock | 231 | $50 | $11.6K | 29,769 |
| 2026-07-17 | Open-market sale | Common Stock | 459 | $52 | $23.7K | 29,310 |
| 2026-07-17 | Open-market sale | Common Stock | 2,063 | $52 | $108.1K | 27,247 |
| 2026-07-17 | Open-market sale | Common Stock | 2,184 | $53 | $116.7K | 25,063 |
| 2026-07-17 | Open-market sale | Common Stock | 63 | $54 | $3.4K | 25,000 |
| 2026-07-17 | Option exercise/conversion | Stock Option (right to buy) | 5,000 | — | — | 116,268 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Option exercise/conversion (5,000 shares) |
| 2026-07-17 | Open-market sale (231 shares) |
| 2026-07-17 | Open-market sale (459 shares) |
| 2026-07-17 | Open-market sale (2,063 shares) |
| 2026-07-17 | Open-market sale (2,184 shares) |
| 2026-07-17 | Open-market sale (63 shares) |
| 2026-07-17 | Option exercise/conversion (5,000 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, Helen Louise Collins
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.